Early results of the selenium and vitamin E prostate cancer prevention study

One randomized, prospective clinical trial for chemoprevention of prostate cancer has been completed, and two additional trials are ongoing. The investment, time, and effort for these trials are substantial. We reviewed the outcomes of these trials to address the value of the investment. The outcomes of the Prostate Cancer Prevention Trial (testing finasteride) and the design of the Selenium and Vitamin E Cancer Prevention Trial (SELECT; testing vitamin E and selenium) trial as well as the Reduction by Dutasteride of Prostate Cancer Events (REDUCE) trial (testing dutasteride) were reviewed. From a public health standpoint, there is tremendous potential for benefit from large-scale cancer prevention trials. Because of the volume of data that are collected, potential discoveries related to the biology of the disease are substantial. Translational scientific efforts are direct outgrowths of these studies. Prospective, randomized chemoprevention trials for prostate and other cancers are expensive and require long periods of time to conduct, yet the rewards are on a par with the investment.

Download Full-text

A Summary of the Prostate Cancer Prevention Trials With a Focus on the Role of Vitamin E

Home Health Care Management & Practice ◽

10.1177/1084822312453048 ◽

2012 ◽

Vol 25 (1) ◽

pp. 23-28 ◽

Cited By ~ 2

Author(s):

Fadi Abu-Shahin ◽

William Stone ◽

Victoria Ramsauer ◽

Koyamangalath Krishnan

Keyword(s):

Prostate Cancer ◽

Vitamin E ◽

Cancer Prevention ◽

Prostate Cancer Prevention ◽

Prevention Trials

Download Full-text

Selenium and Prostate Cancer Prevention: Insights from the Selenium and Vitamin E Cancer Prevention Trial (SELECT)

Nutrients ◽

10.3390/nu5041122 ◽

2013 ◽

Vol 5 (4) ◽

pp. 1122-1148 ◽

Cited By ~ 44

Author(s):

Holly Nicastro ◽

Barbara Dunn

Keyword(s):

Prostate Cancer ◽

Vitamin E ◽

Cancer Prevention ◽

Prevention Trial ◽

Prostate Cancer Prevention

Download Full-text

Methods to Predict and Lower the Risk of Prostate Cancer

The Scientific World JOURNAL ◽

10.1100/tsw.2011.72 ◽

2011 ◽

Vol 11 ◽

pp. 742-748 ◽

Cited By ~ 2

Author(s):

Barbara Ercole ◽

Dipen J. Parekh

Keyword(s):

Prostate Cancer ◽

Vitamin E ◽

Cancer Prevention ◽

Malignant Transformation ◽

Patient Population ◽

Prevention Trial ◽

Reductase Inhibitors ◽

Prostate Cells ◽

Prostate Cancer Prevention ◽

Cancer Multiple

Chemoprevention for prostate cancer (PCa) continues to generate interest from both physicians and the patient population. The goal of chemoprevention is to stop the malignant transformation of prostate cells into cancer. Multiple studies on different substances ranging from supplements to medical therapy have been undertaken. Thus far, only the studies on 5α-reductase inhibitors (the Prostate Cancer Prevention Trial [PCPT] and Reduction by Dutasteride of Prostate Cancer Events [REDUCE] trial) have demonstrated a reduction in the risk of PCa, while results from the Selenium and Vitamin E Cancer Prevention Trial (SELECT) concluded no decreased risk for PCa with selenium or vitamin E.

Download Full-text